ESTRO 2025 - Abstract Book

S847

Clinical - Gynaecology

ESTRO 2025

2964

Digital Poster SBRT TREATMENT IN OLIGOMETASTATIC OVARIAN CANCER

Susana Sánchez Rico 1 , Cristina de la Fuente Alonso 1 , Sofía Córdoba Largo 1 , Beatriz Gil Haro 1 , Sofía Santana 1 , Constanza Maximiano 2 , Mariela Rojas 1 , Sofía Merino 1 , José Cantillana 1 , Arancha Gallego 1 , Jesús Romero 1 1 Radiation Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain. 2 Medical Oncology, Hospital Universitario Puerta de Hierro, Madrid, Spain

Purpose/Objective: The aim of this report is to analyze the local control, disease free survival and systemic free interval in patients with ovarian oligometastasis treated with SBRT.

Material/Methods: In this study we have made a retrospective descriptive analysis of the outcomes of patients treated with SBRT in ovarian cancer. From June 2016 until March 2024 we treated 7 patients (three of them being treated simultaneously with Immunotherapy) with a total of 18 lesions. The most common SBRT schedule was five fractions with a total dose of 35 Gy (66.7%). However, different treatment schemes were used depending on the type of metastasis. (Figure 1). Medians and life tables were computed using the product-limit estimate by the Kaplan and Meier method.